Clinical Trial

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.
Trial Details
NCT Number NCT07708285
Lead Sponsor Beijing Tiantan Hospital
Conditions NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, Meningioma
Enrollment 30 participants
Start Date 2026-07-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16